Published in J Thromb Haemost on July 01, 2013
Antithrombin-binding oligosaccharides: structural diversities in a unique function? Glycoconj J (2014) 0.78
Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost (2007) 3.66
Extended out-of-hospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty: a systematic review. Ann Intern Med (2001) 2.37
Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: a pooled analysis of three trials. Thromb Res (2010) 1.93
Increased plasma serotonin in primary pulmonary hypertension. Am J Med (1995) 1.86
Gradient polyacrylamide gel electrophoresis for determination of molecular weights of heparin preparations and low-molecular-weight heparin derivatives. J Pharm Sci (1992) 1.80
A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost (2005) 1.70
Recommendations on biosimilar low-molecular-weight heparins. J Thromb Haemost (2009) 1.68
[Clinical diagnosis of deep venous thrombosis after hip replacement surgery]. Tidsskr Nor Laegeforen (1997) 1.67
Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med (2002) 1.65
Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation (2001) 1.64
Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. Int Angiol (2001) 1.59
The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost (2003) 1.57
Frequency and timing of clinical venous thromboembolism after major joint surgery. J Bone Joint Surg Br (2006) 1.56
Effects of pneumoperitoneum and reverse Trendelenburg position on cardiopulmonary function in morbidly obese patients receiving laparoscopic gastric banding. Eur J Anaesthesiol (2000) 1.54
Conformer populations of L-iduronic acid residues in glycosaminoglycan sequences. Carbohydr Res (1990) 1.53
Use of prostaglandin E1 for prevention of liver veno-occlusive disease in leukaemic patients treated by allogeneic bone marrow transplantation. Br J Haematol (1990) 1.53
Liver veno-occlusive disease after bone marrow transplantation changes in coagulation parameters and endothelial markers. Thromb Res (1991) 1.51
Effect of nitrous oxide on desflurane MACBAR at two target-controlled concentrations of remifentanil. Minerva Anestesiol (2008) 1.48
A randomized trial of the low-molecular-weight heparin certoparin to prevent restenosis following coronary angioplasty. J Invasive Cardiol (2001) 1.48
Embolic and bleeding events after modified Bentall procedure in selected patients. Heart (2006) 1.47
The effect of adding nitrous oxide on MAC of sevoflurane combined with two target-controlled concentrations of remifentanil in women. Eur J Anaesthesiol (2005) 1.46
Validation of a live animal model for training in endoscopic hemostasis of upper gastrointestinal bleeding ulcers. Endoscopy (2013) 1.46
Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost (2006) 1.44
The effects of single or multiple injections on the volume of 0.5% ropivacaine required for femoral nerve blockade. Anesth Analg (2001) 1.42
Comparison of two PF4/heparin ELISA assays for the laboratory diagnosis of heparin-induced thrombocytopenia. Semin Thromb Hemost (1999) 1.42
Infants with Kasabach-Merritt syndrome do not have "true" hemangiomas. J Pediatr (1997) 1.42
1H and 13C NMR spectral assignments of the major sequences of twelve systematically modified heparin derivatives. Carbohydr Res (1996) 1.41
Laboratory assays for the evaluation of recombinant hirudin. Haemostasis (1991) 1.40
Colposcopy in pregnancy: directed brush cytology compared with cervical biopsy. Obstet Gynecol (1999) 1.39
The structure of heparin oligosaccharide fragments with high anti-(factor Xa) activity containing the minimal antithrombin III-binding sequence. Chemical and 13C nuclear-magnetic-resonance studies. Biochem J (1981) 1.39
Arterial stiffness and cardiovascular risk factors in a population-based study. J Hypertens (2001) 1.29
Cleavage of the antithrombin III binding site in heparin by heparinases and its implication in the generation of low molecular weight heparin. Proc Natl Acad Sci U S A (2000) 1.27
Nerve stimulator and multiple injection technique for upper and lower limb blockade: failure rate, patient acceptance, and neurologic complications. Study Group on Regional Anesthesia. Anesth Analg (1999) 1.25
Isolation and characterization of human heparin. Biochemistry (1992) 1.21
Controversial glycosaminoglycan conformations. Nature (1986) 1.20
Combined quantitative (1)H and (13)C nuclear magnetic resonance spectroscopy for characterization of heparin preparations. Semin Thromb Hemost (2001) 1.19
Coagulation abnormalities associated with extensive venous malformations of the limbs: differentiation from Kasabach-Merritt syndrome. Clin Lab Haematol (2002) 1.19
Respiratory mechanics in anesthetized paralyzed humans: effects of flow, volume, and time. J Appl Physiol (1985) (1989) 1.18
Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J Thromb Haemost (2004) 1.17
Small doses of remifentanil or sufentanil for blunting cardiovascular changes induced by tracheal intubation: a double-blind comparison. Eur J Anaesthesiol (2001) 1.17
Oligosaccharide mapping of low molecular weight heparins: structure and activity differences. J Med Chem (1990) 1.16
Small-dose clonidine prolongs postoperative analgesia after sciatic-femoral nerve block with 0.75% ropivacaine for foot surgery. Anesth Analg (2000) 1.16
Monoclonal antibody to human platelet glycoprotein I. II. Effects on human platelet function. Br J Haematol (1981) 1.15
Cardiovascular effects of two different regional anaesthetic techniques for unilateral leg surgery. Acta Anaesthesiol Scand (1998) 1.15
Renal vascular lesions in lupus nephritis. Medicine (Baltimore) (1997) 1.14
Heparin-like compounds prepared by chemical modification of capsular polysaccharide from E. coli K5. Carbohydr Res (1994) 1.13
Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood (1998) 1.12
Hemostatic effects of aprotinin, tranexamic acid and epsilon-aminocaproic acid in primary cardiac surgery. Ann Thorac Surg (1999) 1.12
A double-blind comparison of ropivacaine, bupivacaine, and mepivacaine during sciatic and femoral nerve blockade. Anesth Analg (1998) 1.12
Isolation of new genes in distal Xq28: transcriptional map and identification of a human homologue of the ARD1 N-acetyl transferase of Saccharomyces cerevisiae. Hum Mol Genet (1994) 1.11
A primate model for prolonged endotoxin shock. Blood-vascular reactions and effects of glucocorticoid treatment. Lab Invest (1978) 1.10
Autologous platelet concentrate for the treatment of full-thickness macular holes. Graefes Arch Clin Exp Ophthalmol (1995) 1.09
Vascular endothelial growth factor confers a growth advantage in vitro and in vivo to stromal cells cultured from neonatal hemangiomas. Am J Pathol (1997) 1.09
Differential distribution of von Willebrand factor in endothelial cells. Comparison between normal pigs and pigs with von Willebrand disease. Arteriosclerosis (1987) 1.09
Pulmonary and chest wall mechanics in anesthetized paralyzed humans. J Appl Physiol (1985) (1991) 1.09
Mono- and bidimensional 500 MHz 1H-NMR spectra of a synthetic pentasaccharide corresponding to the binding sequence of heparin to antithrombin-III: evidence for conformational peculiarity of the sulfated iduronate residue. Biochem Biophys Res Commun (1985) 1.09
Conformation of heparin pentasaccharide bound to antithrombin III. Biochem J (2001) 1.08
Infected joint replacements in HIV-positive patients with haemophilia. J Bone Joint Surg Br (2001) 1.08
Impact of inhaled nitric oxide on platelet aggregation and fibrinolysis in rats with endotoxic lung injury. Role of cyclic guanosine 5'-monophosphate. Am J Respir Crit Care Med (1998) 1.07
Primary pulmonary hypertension in a patient with a familial platelet storage pool disease: role of serotonin. Am J Med (1990) 1.07
High plasma serotonin levels in primary pulmonary hypertension. Effect of long-term epoprostenol (prostacyclin) therapy. Arterioscler Thromb Vasc Biol (2000) 1.07
Effect of nasal pressure support ventilation and external PEEP on diaphragmatic activity in patients with severe stable COPD. Chest (1993) 1.06
Target-controlled infusion during monitored anesthesia care in patients undergoing EUS: propofol alone versus midazolam plus propofol. A prospective double-blind randomised controlled trial. Dig Liver Dis (2006) 1.06
Safety assessment of new antithrombotic agents: lessons from the EXTEND study on ximelagatran. Thromb Res (2008) 1.05
Ropivacaine or 2% mepivacaine for lower limb peripheral nerve blocks. Study Group on Orthopedic Anesthesia of the Italian Society of Anesthesia, Analgesia, and Intensive Care. Anesthesiology (1999) 1.04
Regional cerebral metabolism of glucose in comatose and vegetative state patients. J Neurosurg Anesthesiol (1995) 1.04
Interscalene brachial plexus anaesthesia with 0.5%, 0.75% or 1% ropivacaine: a double-blind comparison with 2% mepivacaine. Br J Anaesth (1999) 1.03
Anti-Xa active heparin oligosaccharides. Thromb Res (1980) 1.03
Structural studies on a biologically active hexasaccharide obtained from heparin. Ann N Y Acad Sci (1981) 1.02
Role of neuropeptides in pathogenesis of reflex sympathetic dystrophy. Acta Orthop Belg (1998) 1.02
Prevention and treatment of venous thromboembolism--International Consensus Statement. Int Angiol (2013) 1.01
Eleven X chromosome breakpoints associated with premature ovarian failure (POF) map to a 15-Mb YAC contig spanning Xq21. Genomics (1997) 1.01
Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery. J Thromb Haemost (2007) 1.00
Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: a systematic review. Arch Intern Med (2001) 1.00
Cardiorespiratory changes during gynaecological laparoscopy by abdominal wall elevation: comparison with carbon dioxide pneumoperitoneum. Br J Anaesth (1997) 0.99
Results of the representative Italian national survey on radon indoors. Health Phys (1996) 0.98
Transcriptional organization of a 450-kb region of the human X chromosome in Xq28. Proc Natl Acad Sci U S A (1993) 0.98
In vivo regulation of von willebrand factor synthesis: von Willebrand factor production in endothelial cells after lung transplantation between normal pigs and von Willebrand factor-deficient pigs. Arterioscler Thromb Vasc Biol (1999) 0.96
Orthopaedic thromboprophylaxis: limitations of current guidelines. J Bone Joint Surg Br (2008) 0.96
Thoracic splenosis. AJR Am J Roentgenol (1985) 0.96
[Guidelines for good clinical practice: prevention and treatment of venous thromboembolism in medical patients]. J Mal Vasc (2010) 0.96
Metabolic syndrome is associated with markers of subclinical atherosclerosis in a French population-based sample. Atherosclerosis (2005) 0.96
Activation of coagulation and fibrinolysis during coronary surgery: on-pump versus off-pump techniques. Anesthesiology (2001) 0.96
Absence of plasma prostacyclin stimulating activity deficiency in hemolytic uremic syndrome. J Pediatr (1987) 0.95
Platelet functions and haemostasis parameters in pigs: absence of side effects of a procedure of general anaesthesia. Thromb Res (1996) 0.95
Midazolam and pethidine versus propofol and fentanyl patient controlled sedation/analgesia for upper gastrointestinal tract ultrasound endoscopy: a prospective randomized controlled trial. Dig Liver Dis (2007) 0.95
Frequency of hypotension during conventional or asymmetric hyperbaric spinal block. Reg Anesth Pain Med (1999) 0.95
Structural characterization of low molecular weight heparins. Semin Thromb Hemost (1999) 0.94
Biosynthesis of heparin. Availability of glucosaminyl 3-O-sulfation sites. J Biol Chem (1990) 0.93
Specific antibodies to diphtheria toxin and type 6A pneumococcal capsular polysaccharide induced by a model of semi-synthetic glycoconjugate antigen. Mol Immunol (1985) 0.93
Fentanyl does not improve the nerve block characteristics of axillary brachial plexus anaesthesia performed with ropivacaine. Acta Anaesthesiol Scand (2001) 0.93
Effect of the thromboxane prostaglandin receptor antagonist terutroban on arterial thrombogenesis after repeated administration in patients treated for the prevention of ischemic stroke. Cerebrovasc Dis (2009) 0.92
Thromboembolism--an academic concern or a clinical reality? Acta Orthop Scand (1999) 0.92
No alteration in platelet function or coagulation induced by EGb761 in a controlled study. Clin Lab Haematol (2003) 0.92
Circadian relationship of serum uric acid and nitric oxide. JAMA (2000) 0.92
Effect of substitution pattern on 1H, 13C NMR chemical shifts and 1J(CH) coupling constants in heparin derivatives. Carbohydr Res (2000) 0.92
Experimental evidence of cerebral injury from profound hypothermia during cardiopulmonary bypass. Pediatr Cardiol (1998) 0.92
Respiratory mechanics during submersion and negative-pressure breathing. J Appl Physiol (1966) 0.92
Clinical assessment of target-controlled infusion of propofol during monitored anesthesia care. Can J Anaesth (1999) 0.92
Pulmonary function changes after interscalene brachial plexus anesthesia with 0.5% and 0.75% ropivacaine: a double-blinded comparison with 2% mepivacaine. Anesth Analg (1999) 0.92